Johnson & Johnson (JNJ)
20 Jan 2017
Thu, Jan 19 2017
New multidistrict litigation over claims that a Sanofi breast cancer drug causes permanent hair loss more than doubled in size over the past month, and plaintiffs are continuing to mount ovarian cancer claims involving Johnson & Johnson's talc products in federal court.
* Johnson & Johnson reports 7.4 percent passive stake in Merus NV as of Dec 31, 2016 - SEC filing Source text: (http://bit.ly/2j9ZI8k) Further company coverage:
BRUSSELS, Jan 18 The following are mergers under review by the European Commission and a brief guide to the EU merger process:
Johnson & Johnson will have to face a retrial of patent infringement claims over contact lens technology after the U.S. Supreme Court on Tuesday refused to review a lower court's decision overturning the company's win at an earlier trial.
Two Johnson & Johnson units have asked a U.S. appeals court to uphold a ruling that blocked a former longtime executive from taking a high-profile role at a rival medical device maker, saying her defection poses an imminent risk to the companies.
* Orthocell announces collaboration with Johnson & Johnson Innovation
ZURICH Johnson & Johnson and Actelion have asked Switzerland's takeover board about the viability of a complicated takeover deal the U.S. healthcare company is discussing with the Swiss biotech firm, newspaper Tages-Anzeiger reported on Friday, without saying how it got the information.
ZURICH, Jan 6 Johnson & Johnson and Actelion have asked Switzerland's takeover board about the viability of a complicated takeover deal the U.S. healthcare company is discussing with the Swiss biotech firm, newspaper Tages-Anzeiger reported on Friday, without saying how it got the information.
A U.S. judge almost halved the award in a December jury verdict that ordered Johnson & Johnson and its DePuy Orthopaedics unit to pay more than $1 billion to plaintiffs in six lawsuits who said they were injured by DePuy's Pinnacle hip implants.
Johnson & Johnson is negotiating a deal to acquire Swiss biotechnology company Actelion Ltd that would separate its commercialized portfolio from its research and development assets, people familiar with the matter said on Thursday.